XM does not provide services to residents of the United States of America.

European healthcare wins as autos lose out



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>LIVE MARKETS-European healthcare wins as autos lose out</title></head><body>

STOXX 600 flat

Energy sector leads

Just Eat surges after unit sale

U.S. futures edge down

Nov 13 (Reuters) -Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com


EUROPEAN HEALTHCARE WINS AS AUTOS LOSE OUT

In a post U.S-election world, new battle lines are being drawn in financial markets as investors mull the implications of possible new tariffs, higher for longer rates and lower corporate taxes.

And market players are already starting to see European healthcare as a winner and autos as a loser.

The region's healthcare stocks .SXDP are down 0.6% since Nov 5th, while autos are off 2.8%. The broader STOXX 600 .STOXX meanwhile is down 1.5%.

Valuation-wise, healthcare stocks are trading on a 12-month forward PE ratio of about 16.2 versus 6.2 for autos, according to LSEG Workspace.

The state of play is reflected in the results of Bank of America's latest European fund manager survey which found healthcare is still the biggest consensus overweight in the European sector space while autos are the least preferred.

So why is healthcare so favoured?

Its defensive nature is in the spotlight, as well as the fact that it benefits from a strong dollar given its earnings breakdown.

In a Wednesday note, Kepler Cheuvreux reiterated its overweight rating on healthcare and semis which they see as "two strong dollar beneficiaries".

JPM equity strategists also highlighted healthcare as a tactical buy on a stronger greenback this week, while they stay short on autos.

It helps that generally defensives are outperforming cyclicals in Europe in terms of EPS beats this reporting season, according to Barclays.

A few big names stand out.

On Tuesday drugmaker AstraZeneca AZN.L lifted its annual sales and profit forecast for the second time this year, and last week Novo Nordisk NOVOb.CO reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug.

Meanwhile in the autos space, Volkswagen Group VOWG_p.DE last month reported a 7% decline in third-quarter global deliveries, while BMW BMWG.DE and Mercedes MBGn.DE flagged sluggish demand and stiff competition in China in their third quarter sales.


(Lucy Raitano)

*****

WEDNESDAY'S OTHER LIVE MARKETS POSTS:

CAUTIOUS START FOR EUROPE AFTER TUESDAY'S SLIDE CLICK HERE

EUROPEAN FUTURES POINT AT FURTHER WEAKNESS CLICK HERE

'TRUMP TRADES' PAUSE FOR BREATH BEFORE US CPI CLICK HERE


Rates and inflation https://tmsnrt.rs/3U8HdD2

European shares mostly higher https://reut.rs/3Z3i1Cb

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.